Good safety profile to the people at almost all ages and during pregnancy
HIV infection, mild/moderate disease
HIV INFECTION, VIRUS, VIRAL SHEDDING
Nelfinavir was approved for HIV infection in adults and adolescents aged 13 and older (750 mg three times a day with meal or 1250 mg twice a day with meal), and children with age from 2 to <13 years (25 to 35 mg/kg three times a day with meal or 45 to 55 mg/kg twice a day with meal). In addition, nelfinavir was found to be safe in children <2 months old, and between 2 months and 2 years oldIn summary, nelfinavir could reduce the activity of SARS-CoV-2 main protease and the virus replication in Vero E6, it is also active in suppressing SARS-CoV-2 shedding in the monkeys and can lower viral replication in the lungs by approximately three orders of magnitude when used prophylactically in a rhesus macaque model. In clinic, nelfinavir has the efficacy to shorten the length of viral shedding in COVID-19 individuals with mild/moderate disease by 5.5 days (